Recent Finacing
Recent Raise
ADmit Therapeutics is an IDIBELL spin‑off developing MAP‑AD, a blood‑based diagnostic and predictive algorithm using mitochondrial DNA methylation to stratify MCI patients by Alzheimer’s progression risk for trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
